53 results about "Propranolol Hydrochloride" patented technology

The invention belongs to the technical field of medicines, and provides a propranolol hydrochloride (PPL.HCL) gel which can be externally used for treating infant superficial hemangioma. The propranolol hydrochloride gel is mainly prepared from propranolol hydrochloride, gel matrix, a percutaneous penetration enhancer, a preservative, a humectant and the like. By using the propranolol hydrochloride gel, adverse reactions such as decreased heart rate, cyanosis, airway hyperresponsiveness, shortage of granular leukocytes, diarrhoea, sleep change and blood sugar reduction caused by orally taking propranolol by hemangioma patients can be reduced and even avoided, and the problems that oral dosage is not easy to control, infants inconveniently take medicines and the like are solved.

The invention discloses a propranolol hydrochloride lipidosome gel, which is prepared by the following bulk drugs and auxiliary materials by weight percent: 0.012-0.075% of propranolol hydrochloride, 0.037-0.150% of phosphatidyl ethanolamine, 0.012-0.075% of cholesterol, 2.5-5% of triethanolamine, 1-2% of carbopol, and the balance of water. According to the propranolol hydrochloride lipidosome gel, during the preparation, the lipidosome is uniformly dispersed in the gel, so that the stability of the lipidosome is improved; the water-soluble gel carbopol has excellent biocompatibility, can be well adhered to skin and cannot stimulate skin; drug administration time is prolonged, the toxic and side effects on the whole body are reduced, the adaptability of patients is improved, and the propranolol hydrochloride lipidosome gel has excellent application prospect.

The invention relates to and belongs to a potentiometric chemical sensor, in particular to a timolol maleate potentiometric chemical sensor and a preparation method thereof. The preparation method comprises the following steps: (1) carrying out the chemical modification by the periodic scanning electro-polymerization method after pre-processing the surface of the matrix electrode to prepare the chemically modified electrode; (2) preparing a PVC-film sensitive solution by the conventional method with the solvent being tetrahydrofuran, and coating the modified electrode with the PVC sensitive film by the dip-coating method to prepare a chemical sensor (I); (3) preparing the molecularly imprinted polymer (Polymer A) of timolol maleate, and preparing the PVC film (Film II) containing Polymer A; and (4) compounding the Film II onto the PVC sensitive film of the chemical sensor I. The invention can effectively overcome the disadvantages of the existence of internal reference solution electrodes in the prior art, furthermore, the chemical sensor of the invention is significantly superior to the existing ion-selective electrodes in term of the selectivity of the drug (such as propranolol hydrochloride and the like) ions with the molecule with the structures, such as alcohol amine, imido and the like.

The invention discloses a percutaneous give drug system, which comprises: a drug storeroom, the gel drug layer comprises drug, solvent, transdermal accelerating agent and gelatinizing agent; one adsorption layer comprised solvent absorption material of solvent in absorbable drug storeroom; one isolating layer between drug storeroom and adsorption layer, which is of non-woven fabrics or semipermeable membrane to make solvent of gas or liquid pass through successfully; adsorption layer can joint isolating layer of drug storeroom in opposite directions of closing up to skin of drug storeroom. The percutaneous give drug system in this invention can increase drug level in drug storeroom of the system to elevate drug transdermal speed, as well as increase controlled release effect of percutaneous give drug and absolute bioavailability, enhance drug curative effect, decrease drug waste, and depress preparation cost of the system. The invention is fit particular to percutaneous give drug system for water-soluble drug of propranolol hydrochloride, verapamil hydrochloride and chlorpromazine hydrochloride.

The invention relates to medicine composition for treating insomnia, which consists of following ingredients in parts by weight: 15 to 35 parts of Chinese angelica, 10 to 30 parts of roots of red-rooted salvia, 15 to 30 parts of radix curcumae, 10 to 25 parts of polygala tenuifolia, 5 to 23 parts of liquorice, 10 to 28 parts of poria with hostwood, 15 to 33 parts of fried spina date seeds, 1 to 15 parts of fructus alpiniae oxyphyllae, 5 to 23 parts of pericarpium citri reticulatae, 4 to 22 parts of platycladi seeds, 6 to 24 parts of calamus, 5 to 23 parts of dragon bone, 15 to 33 parts of rheum officinale, 1 to 15 parts of ligusticum wallichii, 2 to 18 parts of schisandra chinensis, 5 to 23 parts of radix paeoniae alba, 2 to 18 parts of Cape jasmine, 10 to 28 parts of cortex albiziae, 0.4 to 0.7 part of propranolol hydrochloride, 0.4 to 0.7 part of oryzanol and 0.2 to 0.3 part of diazepam tablets. The medicine composition has a function for treating nervous insomnia caused by various reasons, refractory insomnia and insomnia with unknown reasons; and moreover, the medicine composition is remarkable in curative effect, short in treatment process, fast in effectiveness and free from side effect.

The invention relates to a propranolol hydrochloride oral administration emulsion for treating infantile hemangioma and a preparation method thereof. The oral administration emulsion is prepared from 0.25 to 40 parts by weight of propranolol hydrochloride, 70 to 300 parts by weight of oil phase, 22 to 200 parts by weight of emulsifiers, 15 to 101.5 parts by weight of co-emulsifiers and 352 to 1570 parts by weight of purified water. The propranolol hydrochloride oral administration emulsion provided by the invention solves the problem that no special oral administration preparation for treating infantile hemangioma exists in China at present. The propranolol hydrochloride oral administration emulsion provided by the invention overcomes the defect of a phenomenon of tablet and capsule taking difficulty due to infant pharyngeal narrowing. The propranolol hydrochloride is used as an effective ingredient to be uniformly dispersed in the emulsion; the administration dosage can be precisely mastered; the excessive treatment or insufficient treatment can be avoided.

The invention relates to an HPLC (High Performance Liquid Chromatography) detection method for propranolol hydrochloride genotoxic impurities. The method comprises the following steps of: preparing amixed reference substance mother solution from 1-naphthol, naphthyl glycidyl ether and a diluent in a constant-volume manner; preparing a sample solution from propranolol hydrochloride and a diluent in a constant-volume mode; and detecting the mixed reference substance mother solution and the sample solution by adopting a high performance liquid chromatograph to obtain a qualitative and quantitative detection result of propranolol hydrochloride genotoxic impurities 1-naphthol and naphthyl glycidyl ether, wherein the conditions of high performance liquid chromatography as follows: a C18 chromatographic column is adopted; and gradient elution is carried out by taking a phosphoric acid aqueous solution as a mobile phase A and acetonitrile as a mobile phase B at the column temperature of 20-30DEG C and the detection wavelength of 215-220nm. The method has the advantages of good specificity, solution stability, sensitivity, linearity, accuracy, precision and durability, appropriate chromatographic conditions and good separation effect, can meet the requirements of qualitative and quantitative detection, and is beneficial to quality control of genotoxic impurities 1-naphthol and naphthyl glycidyl ether in API so as to monitor the quality of drugs.

The invention discloses propranolole hydrochloride sustained-release pellets and a preparation method thereof. The propranolole hydrochloride sustained-release pellets comprise a coating layer, medicine-containing pellets, Eudragit NE-30D, powdered steatile, sodium dodecyl sulfate or polyethylene glycol; propranolole hydrochloride, blank pellets, a filler, a lubricant and an adhesive. The method employs a novel sustained release preparation and a pellets preparation, slow release means delay of drug release rate of the medicine in a dosage form, absorption rate of medicine in the body can be reduced, more stable treatment effect can be realized; pellets can increase the distribution area of the medicine on the surface of the gastrointestinal tract, irritation is reduced, bioavailability is increased, influence due to stomach evacuation factor is not generated, medicine can be uniformly absorbed in the body, individual difference is little, and simultaneous application of two advanced technologies enhances the technical advantage of the propranolole hydrochloride sustained-release pellets.

The invention provides a propranolol hydrochloride gel preparation for external use and a preparation method and application thereof. The propranolol hydrochloride gel preparation for the external use contains at least 3% by weight of propranolol hydrochloride. The propranolol hydrochloride gel preparation for the external use has good stability and skin permeability and has a significant curative effect on treatment and prevention of infantile hemangioma located in different subcutaneous depths.

The invention uses super micro shattering and propranolol drop pills producing the technology to produce fenfluramine drop pills, reaching the purposes such as increasing speed, and dissolution of disintegration, increasing the medicine stability, reducing the dose of auxiliary materials and decreasing cost, with rapid effect and convenient use. It can be buccal as well as deglutition, has remarkable conformity, and is especially suitable for children, older man, sicker in bed or with difficulty of swallowing.

The invention provides a propranolol hydrochloride smearing preparation and a preparation method and application thereof. The propranolol hydrochloride smearing preparation is prepared from, by weight, 1%-8% of propranolol hydrochloride, 2.5%-15% of substrate, 2%-10% of skin penetration enhancer, 3%-16% of moisturizing agent, 0.02%-0.2% of bacteriostatic agent and the balance water. The propranolol hydrochloride smearing preparation is small in skin irritation and capable of directly acting on infantile hemangioma ulcer parts to rapidly facilitate ulcer healing and treating hemangioma simultaneously.

The invention discloses a synthesis method of propranolol hydrochloride. The synthesis method of propranolol hydrochloride comprises the following steps: by taking menaphthol and epoxy chloropropane as raw materials, carrying out etherification reaction under an alkaline condition and under the action of a phase transfer catalyst to obtain a key intermediate 3-(1-naphthoxy)-1, 2-epoxypropane; carrying out ring-opening reaction and salifying reaction on the 3-(1-naphthoxy)-1, 2-epoxypropane and isopropylamine under the catalytic action of alkali to obtain a crude propranolol hydrochloride product; and finally refining the crude propranolol hydrochloride product to obtain propranolol hydrochloride with the purity of 99.8% or above. The synthesis method is a preparation method which is shortin synthesis route, simple to operate and suitable for industrial production.

The invention relates to compound propranolol hydrochloride oral liquid for treating infantile hemangiomas. The compound propranolol hydrochloride oral liquid comprises the following raw materials byweight of 100-300g of endothelium corneum gigeriae galli, 200-400g of haws, 100-300g of duchesnea indica, 200-300g of bigleaf beautyberry leaves, 200-400g of radix salviae miltiorrhizae, 100-300g of lotus leaves and 30-50g of propranolol hydrochloride. Compared with the prior art, the compound propranolol hydrochloride oral liquid disclosed by the invention has the advantages that the quality andthe effects are notably improved, and the compound propranolol hydrochloride oral liquid is high in cure rate, low in adverse reaction rate, good in mouth feel, easy in infantile administration, smallin dosage and good in biological availability and have enormous social and economic benefits.

The present invention relates to applications of compound gymnadenia conopsea (l.) r. br pills in preparation of essential tremor treating drugs, and belongs to the field of medicine. According to the present invention, the technical prejudice in the application field in the prior art is overcome; and clinical research results show that symptoms of the essential tremor can be significantly improved and the essential tremor treating effect can be achieved by separately using the compound gymnadenia conopsea (l.) r. br pills or combining the compound gymnadenia conopsea (l.) r. br pills and other drugs, the effect of the single use of the compound gymnadenia conopsea (l.) r. br pills is equivalent to the effect of the conventional drug propranolol hydrochloride, and the effect of the combination of the compound gymnadenia conopsea (l.) r. br pills, the nerve calming pills and/or propranolol hydrochloride is superior to the effect of the conventional drug propranolol hydrochloride (P <0.05).

The invention discloses a medicinal composition for preparing an orally-taken sustained-release preparation. Active ingredients of the medicinal composition comprises amlodipine besylate or propranolol hydrochloride or salbutamol sulfate. A sustained release polymer in the medicinal composition is a cellulose derivative, an acrylic acid or methylacrylic acid derivative, or a carbohydrate-based polymer and the like. The sustained release solid composition containing the amlodipine besylate, or the propranolol hydrochloride or the salbutamol sulfate can be prepared into preparation forms such as sustained-release watered pills, various skeleton sustained release preparations, coating sustained release preparations, sustained release capsules, sustained release medical membranes, resin drug sustained release preparations, liquid sustained release preparations.

The invention relates to a felodipine propranolol hydrochloride compound preparation and a preparation method thereof. The felodipine propranolol hydrochloride compound preparation comprises an inner layer and an outer layer, wherein the active ingredient of the inner layer is propranolol hydrochloride; the active ingredient of the outer layer is felodipine; and the outer layer is wrapped outside the inner layer. The felodipine and propranolol hydrochloride are combined for use, so that the antihypertensive effect can be achieved, and propranolol hydrochloride can resist the effect of heart rate increase caused by long-term administration of felodipine.